Physician's Weekly

JUNE 25, 2025

from Oslo University Hospital in Norway, and colleagues examined the efficacy and safety of FMT in primary CDI in a randomized, open-label, noninferiority trial. The groups did not have any significant differences in adverse events. Frederik Emil Juul, M.D., percent of patients receiving FMT and vancomycin, respectively.

Internal Medicine 52

Internal Medicine Hospital Clinic Patients 52

Physician's Weekly

JUNE 18, 2025

For each diet, adverse events were infrequent. The first three weeks of each diet were when most blood pressure reduction occurred. The effect of sodium reduction appeared stronger than the effect of the DASH4D diet. also from Johns Hopkins University, said in a statement.

Diabetes 71

Diabetes Internal Medicine Hypertension Clinic 71

Physician's Weekly

JUNE 25, 2025

Mild-to-moderate gastrointestinal events were the most common adverse events with orforglipron. From baseline to week 40, the percent change in body weight was −4.5, −5.8, percent with the 3-mg, 12-mg, and 36-mg doses, respectively, and −1.7 percent with placebo.

Diabetes 52

Diabetes Clinic Medical Family Practice 52

Physician's Weekly

JUNE 11, 2025

The most common adverse event reported in patients treated with Widaplik was symptomatic low blood pressure. The FDA approval is based on positive results from two international phase 3 trials that compared Widaplik to dual combinations of its component drugs as well as to placebo.

Hypertension 52

Hypertension Diabetes Patients Medical 52

Physician's Weekly

JUNE 25, 2025

percent in indoor activities were seen in counties in Oregon and Washington, respectively, during the wildfire events; increases of 11 and 16 percent were experienced in major cities like Portland and Seattle. Average increases of 10.8

IT 52

IT Family Practice Internal Medicine Primary Care 52